KEROS THERAPEUTICS INC (KROS) Stock Price, Quote, News and Overview
NASDAQ:KROS - Nasdaq - US4923271013 - Common Stock - Currency: USD
KROS Quote, Performance and Key Statistics
11.02
-0.01 (-0.09%)
The current stock price of KROS is 11.02 USD. In the past month the price decreased by -8.32%. In the past year, price decreased by -82.68%.
KROS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KROS
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 160 full-time employees. The company went IPO on 2020-04-08. The company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Company Info
KEROS THERAPEUTICS INC
1050 Waltham Street, Suite 302
Lexington MASSACHUSETTS 02421 US
CEO: Jasbir Seehra
Employees: 160
Company Website: https://www.kerostx.com/
Investor Relations: https://ir.kerostx.com/
Phone: 16173146297
KEROS THERAPEUTICS INC / KROS FAQ
What is the stock price of KEROS THERAPEUTICS INC today?
The current stock price of KROS is 11.02 USD. The price decreased by -0.09% in the last trading session.
What is the ticker symbol for KEROS THERAPEUTICS INC stock?
The exchange symbol of KEROS THERAPEUTICS INC is KROS and it is listed on the Nasdaq exchange.
On which exchange is KROS stock listed?
KROS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KEROS THERAPEUTICS INC stock?
20 analysts have analysed KROS and the average price target is 30.8 USD. This implies a price increase of 179.53% is expected in the next year compared to the current price of 11.02. Check the KEROS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KEROS THERAPEUTICS INC worth?
KEROS THERAPEUTICS INC (KROS) has a market capitalization of 446.42M USD. This makes KROS a Small Cap stock.
How many employees does KEROS THERAPEUTICS INC have?
KEROS THERAPEUTICS INC (KROS) currently has 160 employees.
What are the support and resistance levels for KEROS THERAPEUTICS INC (KROS) stock?
KEROS THERAPEUTICS INC (KROS) has a resistance level at 11.03. Check the full technical report for a detailed analysis of KROS support and resistance levels.
Is KEROS THERAPEUTICS INC (KROS) expected to grow?
The Revenue of KEROS THERAPEUTICS INC (KROS) is expected to grow by 15528.3% in the next year. Check the estimates tab for more information on the KROS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KEROS THERAPEUTICS INC (KROS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KROS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KROS, evaluating the profitability, health, valuation and growth aspects
- KEROS THERAPEUTICS INC (KROS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KEROS THERAPEUTICS INC (KROS) Sales and EPS estimates to see what analysts future expectations are.
- KEROS THERAPEUTICS INC (KROS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KEROS THERAPEUTICS INC (KROS) Insider and Institutional Ownership to learn about the owners and their transactions.
- KEROS THERAPEUTICS INC (KROS) Stock Chart to make your own analysis
- KEROS THERAPEUTICS INC (KROS) Latest news and press-releases to stay up to date.
Does KEROS THERAPEUTICS INC (KROS) stock pay dividends?
KROS does not pay a dividend.
When does KEROS THERAPEUTICS INC (KROS) report earnings?
KEROS THERAPEUTICS INC (KROS) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of KEROS THERAPEUTICS INC (KROS)?
KEROS THERAPEUTICS INC (KROS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.21).
What is the Short Interest ratio of KEROS THERAPEUTICS INC (KROS) stock?
The outstanding short interest for KEROS THERAPEUTICS INC (KROS) is 11.02% of its float. Check the ownership tab for more information on the KROS short interest.
KROS Technical Analysis
KROS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KROS. KROS has a great financial health rating, but its profitability evaluates not so good.
KROS Financial Highlights
Over the last trailing twelve months KROS reported a non-GAAP Earnings per Share(EPS) of -5.21. The EPS decreased by -5.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.34% | ||
| ROE | -34.08% | ||
| Debt/Equity | 0 |
KROS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to KROS. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -1.8% and a revenue growth 15528.3% for KROS